Advertisement

Topics

HIV-1 Envelope FRETted Over by Antibodies.

08:00 EDT 12th June 2019 | BioPortfolio

Summary of "HIV-1 Envelope FRETted Over by Antibodies."

The HIV-1 Envelope (Env) is a metastable protein that displays several conformational states. In recent works, Lu et al. (2019) in Nature and Alsahafi et al. (2019) in Cell Host & Microbe show that antibodies displaying neutralization or antibody-dependent cellular cytotoxicity (ADCC) target different conformations of the viral glycoprotein.

Affiliation

Journal Details

This article was published in the following journal.

Name: Cell host & microbe
ISSN: 1934-6069
Pages: 767-768

Links

DeepDyve research library

PubMed Articles [2178 Associated PubMed Articles listed on BioPortfolio]

Probing the Antigenicity of HCV Envelope Glycoproteins by Phage Display Antibody Technology.

The envelope glycoproteins E1 and E2 of hepatitis C virus form a heterodimeric complex on the viral surface. They are the targets of neutralizing antibodies and are being investigated as potential vac...

HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells.

Mucosal immune responses to HIV-1 involve the recognition of the viral envelope glycoprotein (gp)160 by tissue-resident B cells and subsequent secretion of antibodies. To characterize the B cells "sen...

Detection of Antibodies to HCV E1E2 by Lectin-Capture ELISA.

Enzyme-linked immunosorbent assays (ELISAs) enable rapid detection and quantitation of antibodies in samples. Such assays can be highly sensitive and can be performed in most laboratories with basic e...

An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity.

The HIV-1 envelope glycoprotein (Env) (gp120-gp41) is the target for neutralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC). HIV-1 Env is flexible, sampling different conformation...

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.

VRC01 broadly neutralizing antibodies (bnAbs) target the CD4-binding site (CD4) of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env). Unlike mature antibodies, corresponding VRC01...

Clinical Trials [1675 Associated Clinical Trials listed on BioPortfolio]

A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)

Primary: To determine whether additional boosting with soluble recombinant gp160 vaccine (VaxSyn) after priming with a vaccinia-HIV envelope recombinant (HIVAC-1e) provides a significant a...

Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine

ACTHIVE-001 is a randomised, open-label, uncontrolled phase 1 clinical trial to determine the safety profile of the native-like HIV-1 envelope vaccine, ConM SOSIP.v7, adjuvanted with monop...

Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens

EVAI2020_01 is a single blinded two part experimental medicine study to determine the extent to which different prime-boost combinations of model immunogens based on HIV-1 envelope protein...

Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)

To determine if priming (giving the first vaccination) with a vaccinia recombinant (HIVAC-1e) provides a significant advantage in immunogenicity (production of antibodies) compared to prim...

HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy

Hepatitis B virus (HBV) infection remains difficult to eradicate with about 240 million people living with HBV chronic infection. HBsAg clearance, correlated with a good clinical prognosis...

Medical and Biotech [MESH] Definitions

Antibodies to the HEPATITIS A ANTIGENS including antibodies to envelope, core, and non-structural proteins.

Antibodies to the HEPATITIS C ANTIGENS including antibodies to envelope, core, and non-structural proteins.

An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kDa and contains numerous glycosylation sites. It serves as a precursor for both the HIV ENVELOPE PROTEIN GP120 and the HIV ENVELOPE PROTEIN GP41.

Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)

Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Searches Linking to this Article